Key Highlights
● BAX closed at $24.33 on 9 October 2026, with two data sets disagreeing sharply on the average analyst target, at $21.73 and $28.73.
● The second data set's targets were last updated on 13 August 2026 and appear stale, so no single consensus figure is presented.
● Market data shows one Buy, nine Hold and three Sell ratings, a Reduce consensus.
● Barclays initiated at Underweight with a $20 target on 7 October, and Citigroup lowered its target to $27 from $28 on 5 October.
Baxter International Inc. (NYSE:BAX) is a member of the S&P 500 and closed at $24.33 on Friday 9 October 2026. The medical products company has attracted fresh broker attention in recent days, with a new coverage initiation and a target reduction both appearing in the first week of October.
What Is the Latest Analyst Price Target?
The two data sets differ widely, so no single consensus figure is presented here. Market data shows a consensus target of $21.73, with a high of $27.00 and a low of $15.00, based on 13 ratings in the last 12 months. The second data set, citing third-party data, shows a mean of $28.73, a median of $28.00, a high of $40.00 and a low of $23.00 across 13 analysts. However, that page quotes a price of $23.49 from 2 October 2026 and says its targets were last updated on 13 August 2026, so it appears to be stale.
What Are Wall Street Analysts Saying?
Market data records one Buy, nine Hold and three Sell ratings, giving a consensus rating of "Reduce". The second data set describes the consensus as Hold. Both point to a cautious Street, with few analysts openly positive.
Named broker actions shown on market data include Barclays (Matt Miksic), which initiated coverage on 7 October 2026 with an Underweight rating and a $20.00 target. Citigroup (Joanne Wuensch) lowered its target from $28.00 to $27.00 on 5 October 2026 with a Neutral rating. In late July, Wells Fargo (Larry Biegelsen) raised its target from $19.00 to $23.00, UBS (Patrick Wood) from $19.00 to $25.00, Stifel Nicolaus (Rick Wise) from $19.00 to $24.00 and TD Cowen (Joshua Jennings) from $20.00 to $24.00, all with Hold-equivalent ratings. Goldman Sachs (David Roman) lifted its target from $19.00 to $21.00 on 15 July 2026.
What Could Help the Stock Reach the Price Target?
Market data states that second-quarter 2026 earnings per share were $0.56 against an expected $0.37, and that full-year 2026 guidance was raised to $1.95 to $2.15. That is consistent with the upward target revisions that followed in late July.
Continued execution on earnings and cost control could encourage further upward revisions.
What Could Prevent the Stock Reaching the Target?
The ratings split leans cautious, with three Sell ratings and nine Holds. Barclays' Underweight initiation with a $20.00 target sits below the current share price, and Citigroup trimmed its target in early October. Any earnings disappointment, guidance cut or setback in operations could prompt further reductions.
What Should Investors Watch Next?
Items to watch include further target revisions and guidance updates.
Baxter's Cautious Panel and Conflicting Data Sets Leave No Clean Consensus
Baxter closed at $24.33 on 9 October 2026, and the two data sets diverge by roughly a third, with market data at $21.73 and the second data set at $28.73, though the latter's targets were last updated in mid-August. The ratings are the clearer signal: one Buy, nine Hold and three Sell in market data, with Barclays' Underweight initiation at $20 sitting below the share price. Recent named targets run from $20.00 to $27.00, and market data's reported second-quarter earnings per share of $0.56 against $0.37 and raised full-year guidance of $1.95 to $2.15 are consistent with the late-July target increases.






Please wait processing your request...